U.S. markets closed

Lexicon Pharmaceuticals, Inc. (LXRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.8400-0.0200 (-1.08%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close1.8600
Open1.8500
Bid1.8100 x 4000
Ask1.8400 x 4000
Day's Range1.8100 - 1.8550
52 Week Range1.2200 - 5.3300
Volume1,097,954
Avg. Volume1,743,479
Market Cap197.075M
Beta (5Y Monthly)1.10
PE Ratio (TTM)4.99
EPS (TTM)0.3690
Earnings DateNov 05, 2020 - Nov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
197% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Benzinga

    5 Value Stocks To Watch In The Healthcare Sector

    What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.Below is a list of notable value stocks in the healthcare sector: 1. Ocugen (NASDAQ: OCGN) - P/E: 0.1 2. Lexicon Pharmaceuticals (NASDAQ: LXRX) - P/E: 5.94 3. Hepion Pharmaceuticals (NASDAQ: HEPA) - P/E: 3.95 4. Global Cord Blood (NYSE: CO) - P/E: 6.85 5. Five Star Senior Living (NASDAQ: FVE) - P/E: 3.5Ocugen saw a decrease in earnings per share from 0.89 in Q4 to -0.07 now. Ocugen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Lexicon Pharmaceuticals has reported Q2 earnings per share at -0.65, which has decreased by 3.17% compared to Q1, which was -0.63. Lexicon Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.This quarter, Hepion Pharmaceuticals experienced a decrease in earnings per share, which was -0.92 in Q4 and is now -0.97. Hepion Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Global Cord Blood has reported Q4 earnings per share at 0.11, which has decreased by 35.29% compared to Q3, which was 0.17. Global Cord Blood does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Five Star Senior Living has reported Q2 earnings per share at 0.1, which has increased by 118.18% compared to Q1, which was -0.55. Five Star Senior Living does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.See more from Benzinga * Overview Of Value Stocks In The Real Estate Sector * Analyzing Delta Air Lines's Unusual Options Activity * Analyzing Carnival's Unusual Options Activity(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GTCR and TerSera Therapeutics Announce Acquisition of Xermelo
    PR Newswire

    GTCR and TerSera Therapeutics Announce Acquisition of Xermelo

    GTCR, a leading private equity firm, announced today that its TerSera Therapeutics LLC ("TerSera") portfolio company has entered into a definitive agreement to acquire the product Xermelo® (telotristat ethyl) from Lexicon Pharmaceuticals, Inc. ("Lexicon"; NASDAQ:LXRX) for an upfront purchase price of approximately $159 million plus potential milestone payments based on development and commercialization of Xermelo in a new indication.

  • What You Need To Know About The Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Analyst Downgrade Today
    Simply Wall St.

    What You Need To Know About The Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Analyst Downgrade Today

    One thing we could say about the analysts on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - they aren't optimistic...